These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26125054)

  • 1. The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.
    Lessing C; Ashton T; Davis PB
    J Prim Health Care; 2015 Jun; 7(2):94-101. PubMed ID: 26125054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment.
    Lessing C; Ashton T; Davis P
    Adm Policy Ment Health; 2015 Nov; 42(6):695-703. PubMed ID: 25331449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Evaluation of Health Service Impacts Consequent to Switching from Brand to Generic Venlafaxine in New Zealand under Conditions of Price Neutrality.
    Lessing C; Ashton T; Davis P
    Value Health; 2015 Jul; 18(5):646-54. PubMed ID: 26297093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Zealand patients' understanding of brand substitution and opinions on copayment options for choice of medicine brand.
    Lessing C; Ashton T; Davis P
    Aust Health Rev; 2016 Jun; 40(3):345-350. PubMed ID: 26363980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
    Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
    Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics?
    Sun J; Ren L; Wirtz V
    J Med Econ; 2016 Sep; 19(9):881-8. PubMed ID: 27100310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic Olanzapine Substitution in Patients With Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching.
    Italiano D; Bruno A; Santoro V; Lanza G; Muscatello MR; Zoccali R; Spina E
    Ther Drug Monit; 2015 Dec; 37(6):827-30. PubMed ID: 25830930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
    Rathe JØ
    Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Finland.
    Koskinen H; Mikkola H; Saastamoinen LK; Ahola E; Martikainen JE
    Value Health; 2015 Dec; 18(8):1105-12. PubMed ID: 26686797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
    Kwong WJ; Kamat S; Fang C
    Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
    Layton S; Barbeau M
    Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].
    Bret P; Bonnet F; Bret MC; Jaffré A
    Encephale; 2002; 28(4):329-42. PubMed ID: 12232542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of akathisia after switching from branded to generic high-dose olanzapine.
    Goldberg JF
    J Clin Psychiatry; 2012 Apr; 73(4):497. PubMed ID: 22579148
    [No Abstract]   [Full Text] [Related]  

  • 17. Encouraging the use of generic medicines: implications for transition economies.
    King DR; Kanavos P
    Croat Med J; 2002 Aug; 43(4):462-9. PubMed ID: 12187525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valid grounds for the switch of original antipsychotics with generics.
    Ruzić K; Dadić-Hero E; Knez R; Medved P; Graovac M
    Psychiatr Danub; 2010 Mar; 22(1):102-4. PubMed ID: 20305601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.
    Samuel R; Attard A; Kyriakopoulos M
    BMC Psychiatry; 2013 Oct; 13():244. PubMed ID: 24094081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-saving effects of olanzapine as long-term treatment for bipolar disorder.
    Zhang Y
    J Ment Health Policy Econ; 2008 Sep; 11(3):135-46. PubMed ID: 18806303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.